SecBot SecBot
6-K ·Filed May 11, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonmonths Processed6mo ago SEC0001575872-26-000280
Notable filing: 6-K
Actionable Insight • Neutral

Routine ESOP grant with no immediate trading implications. Monitor next quarterly filing for potential modest dilution impact from option exercises, though 3-year vesting makes this a distant consideration.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.14
T+0 close · May 11, 2026 · via day close
Latest settled
−7.61%
T+60 · $12.14
Vs SPY
−12.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $13.14entry
  2. T+1 · 6mo ago −5.17%α −5.04% · $12.46
  3. T+5 · 6mo ago +3.50%α +3.59% · $13.60
  4. T+20 · 5mo ago +1.75%α +2.05% · $13.37
  5. T+60 · 3mo ago −7.61%α −12.00% · $12.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock options) to eligible employees under existing ESOP schemes at an exercise price of Rs. 1,293.90 per share. This is a routine employee compensation event with no material financial impact or strategic significance.

Key Facts

  • Grant of 816,119 Indian stock options under Dr. Reddy's Employees Stock Option Scheme, 2018
  • Grant of 376,115 ADR stock options under Dr. Reddy's Employees ADR Stock Option Scheme, 2007
  • Exercise price of Rs. 1,293.90 per share for both tranches
  • 100% vesting at the end of 3 years for both option types
  • Approved by Nomination, Governance and Compensation Committee on May 11, 2026

Financial Impact

No material financial impact, standard employee stock compensation grant with 3-year vesting; dilution is minimal relative to total shares outstanding

dilution

Risk Factors

  • Minimal dilution risk from eventual option exercises over 3-year vesting period

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000280
Document: 0001575872-26-000280-index.html0001575872-26-000280
Document: 0001575872-26-000280.txt0001575872-26-000280

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026